Motif Bio looking at US offering and listing

Clinical stage biopharmaceutical company Motif Bio announced on Wednesday that it has filed a registration statement with the US Securities and Exchange Commission relating to a proposed public offering of American depositary shares.

The AIM-traded firm said it has also applied to have the shares listed on the NASDAQ Global Select Market under the ticker symbol ‘MTFB’.

Following completion of the offering, Motif Bio’s ordinary shares will continue to trade on the AIM market, the company confirmed, adding that the number of shares to be offered and the price per share for the offering have not yet been determined.